oral glp-1 agonist for type 2 diabetes drugs Medication Options GLP-1 drugs: Lower dose or – Orforglipron, an Oral Small-Molecule GLP-1

L-carnitine and acetyl-L-carnitine enhance mitochondrial activity and energy metabolism by restoring the NAD(H)/NADP(H) ratio, thereby mitigating ROS-induced damage

This adjusted value considers the complexity of the model and penalizes the inclusion of unnecessary variables

Competitive radioligand binding assays reveal concentration-dependent displacement curves, indicating specific receptor engagement at nanomolar concentrations

hCiPSC treatment partially reversed this dysbiotic state, reducing the abundance of Pseudomonadota and Deferribacterota and promoting the recovery of Bacteroidota and Verrucomicrobiota